Omalizumab for Steroid Reduction in Asthma

Evidence for Steroid-Sparing Effect

• The 2024 ISHAM-ABPA Working Group guidelines recommend omalizumab for treatment-dependent allergic bronchopulmonary aspergillosis (ABPA), demonstrating reduction in oral glucocorticoid dose, improvement in symptoms, and reduction in exacerbations and asthma hospitalizations 2, 3

Patient Selection Criteria

• The National Asthma Education and Prevention Program (NAEPP) guidelines recommend omalizumab for patients aged 12 years and older with severe persistent allergic asthma whose symptoms remain inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists 1

Critical Safety Requirements

• Omalizumab must be administered in a healthcare setting by providers trained to recognize and treat anaphylaxis, with an observed anaphylaxis risk of approximately 0.09% 1